Newborn affected by maternal use of nutritional chemical substances
ICD-10 P04.5 is a billable code used to indicate a diagnosis of newborn affected by maternal use of nutritional chemical substances.
P04.5 refers to newborns who are affected by maternal consumption of nutritional chemical substances, particularly those that are noxious and can be transmitted through the placenta or breast milk. This includes substances such as drugs, alcohol, and tobacco. Maternal drug use can lead to a range of neonatal complications, including withdrawal symptoms, low birth weight, and developmental delays. Alcohol consumption during pregnancy can result in fetal alcohol spectrum disorders, which may manifest as physical, behavioral, and learning problems in the newborn. Tobacco use is associated with intrauterine growth restriction and increased risk of preterm birth. Accurate coding of this condition requires thorough documentation of maternal substance use, the newborn's clinical presentation, and any interventions required. Understanding the implications of these substances on neonatal health is crucial for appropriate management and follow-up care.
Neonatal documentation must include detailed maternal history, substance use specifics, and newborn assessment findings.
Common scenarios include newborns presenting with withdrawal symptoms, low birth weight, or developmental delays due to maternal substance use.
Considerations include the need for multidisciplinary care and potential long-term follow-up for developmental assessments.
Pediatric documentation should reflect ongoing assessments of developmental milestones and any interventions initiated due to maternal substance exposure.
Pediatric scenarios may involve managing behavioral issues or learning disabilities stemming from prenatal exposure.
Pediatricians should be aware of the long-term implications of prenatal substance exposure on child development.
Used when a newborn affected by maternal substance use requires initial assessment and management.
Documentation must include maternal history and newborn assessment findings.
Neonatologists should ensure comprehensive evaluations are performed.
Documentation must include a detailed maternal history of substance use, the newborn's clinical presentation, and any interventions or treatments provided. This ensures accurate coding and appropriate care management.
